Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 29, 1226-1232, June 1, 1969]
© 1969 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schein, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schein, P. S.

1-Methyl-1-nitrosourea and Dialkylnitrosamine Depression of Nicotinamide Adenine Dinucleotide

Philip S. Schein1

Laboratory of Chemical Pharmacology, National Cancer Institute, Bethesda, Maryland 20014

1-Methyl-1-nitrosourea (MNU), the active moiety of the Streptozotocin molecule, produces a dose-related depression of nicotinamide adenine dinucleotide (NAD) concentrations in mouse liver and L1210 ascities, similar to that produced by the latter compound. There was early increase in liver NAD glycohydrolase activity, but no significant change in NAD pyrophosphorylase. While pretreatment with nicotinamide prevented the decrease in NAD, it did not influence either toxicity or antitumor activity of MNU. Unlike Streptozotocin, MNU is nondiabetogenic but does produce severe leukopenia and an acute neurologic syndrome consisting of spasmodic arching of the back and spreading of the limbs. A colorimetric method for the determination of MNU in biologic materials is presented. Eighty-five percent of a 100 mg/kg dose could be accounted for in serum at five minutes, with a half-life of twenty-five minutes. The liver retained 3.6 percent of the total dose at five minutes, with a half-life of 12 minutes, and no drug detectable at two hours. N-Nitrosodimethylamine, N-nitrosodiethylamine, 2-chloro-N-methyl-N-nitrosoethylamine, and N-methyl-N-nitrosourethane have been found to significantly lower liver, but not L1210, NAD concentrations. The possibility of a common mechanism of alkylation, through a diazoalkane intermediate, for the phenomenon of NAD depression is discussed.

1 Present address: Department of Medicine, Beth Israel Hospital, 330 Brookline Avenue, Boston, Massachusetts 02215.

Received 6/17/68. Accepted 1/19/69.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1969 by the American Association for Cancer Research.